Head-to-head · WeighScore
Aurelius Health Group vs HealthRX
The verdict
HealthRX takes it — 86.1/100 to 60.8/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aurelius Health Group | HealthRX |
|---|---|---|
| WeighScore | 60.8/100 | 86.1/100 |
| Grade | C | B |
| Scorecard rank | #311 | #8 |
| Semaglutide | Not disclosed | $189/mo |
| Tirzepatide | $199/mo (microdose tier, compounded) | $349/mo |
| Coverage | Coverage not published | Not publicly listed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #311 · C
Strengths
- Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
- LegitScript Certified
- Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
- Unusually candid about the limited evidence base for microdosing
Where it loses points
- The advertised $89 is a first-month new-patient rate; every month after it is $199
- This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
- No state count is published, only 'most US states', confirmed at intake
- The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
- Compounded tirzepatide is not an FDA-approved finished product
Graded #8 · B
Strengths
- LegitScript-certified (#50087439) — a genuine, verifiable trust signal
- Physician-supervised intake with licensed providers
- Both molecules plus a rare oral GLP tablet option
- Transparent flat monthly pricing, no insurance required
Where it loses points
- Compounded semaglutide/tirzepatide is not FDA-approved
- Some tiers are company-stated and the public site is thin
- Brand Ozempic is a steep pass-through (~$1,299)
- State count is not publicly listed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.